Sudden Sensorineural Hearing Loss Clinical Trial
Official title:
The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss
Migraine and sudden sensorineural hearing loss(SSNHL) are two related disorders. A systemic steroid is usually used to treat SSNHL but the role of migraine prophylaxis medication remained unknown. Mehdi Abouzari et al. found a better improvement when combining topiramate and nortriptyline with steroids in a retrospective study. However, a prospective study with randomization is needed to elucidate the efficacy of these agents. This is a clinical study using medication approved and currently prescribed in the clinic. The included patients were those who came to the clinic and were diagnosed with SSNHL within 14 days of onset. Those patients were asked whether they agreed to participate in this clinical trial. Patients who were diagnosed with SSNHL but were later found to be other diseases such as Meniere's disease and cerebellopontine angle will be excluded from this study. The involved patients were randomized divided into two groups. Both groups received systemic steroids with/without intratympanic steroids. The experimental group receives additional oral topiramate for 6 weeks. Follow-up time is at least 3 months. This study is multi-center. Location of the study is performed at Chang gung memorial hospital Linkou branch, Taipei branch, Taoyuan branch, and New Taipei Municipal Tucheng Hospital.
Once the patients were diagnosed with SSNHL, detailed information of the clinical trial will be introduced. If the patient agreed to participate, he/she will be randomized. The experimental group receives additional oral topiramate for 6 weeks. Both groups follow up at the clinic for at least 3 months. The pure tone audiometry and speech audiometry will be measured at the initial and end of follow-up. Patients who were later diagnosed with cerebellopontine angle tumors, stroke, or Meniere's disease, will be excluded from this study. The audiometry and other hearing outcomes will be analyzed at the end of the study. The treatment efficacy, and prognostic factors will be analyzed and reported. Data regarding adverse effects and drop-out will also be collected and reported. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04120116 -
FX-322 in Adults With Stable Sensorineural Hearing Loss
|
Phase 2 | |
| Not yet recruiting |
NCT05608161 -
Speech Perception Impairment Follow Complete Recovery of Sudden Sensorineural Hearing Loss
|
||
| Recruiting |
NCT04961099 -
Phase I Clinical Study of HY01 in Patients
|
Phase 1 | |
| Recruiting |
NCT06278129 -
Evaluation of the Diagnostic and Prognostic Efficacy of MRI in Acute Sensorineural Hearing Loss and Ménière's Disease
|
||
| Recruiting |
NCT06249919 -
A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04826237 -
Oral Statins and Protection From Hearing Loss
|
Phase 4 | |
| Recruiting |
NCT05849519 -
Small Sample，Unicentric，Randomized, Controlled Clinical Study of Coenzyme I for Injection in the Treatment of Sudden Sensorineural Hearing Loss
|
Early Phase 1 | |
| Not yet recruiting |
NCT04224909 -
Video HIT in Sudden Sensorineural Hearing Loss
|
||
| Not yet recruiting |
NCT06365775 -
Multi-omics Characteristics and Prognosis of Idiopathic Sudden Sensorineural Hearing Loss
|
||
| Not yet recruiting |
NCT06355102 -
The Development of Tinnitus in Patients With SSNHL: Insights From fMRI and Metabolomics
|